As a result, antibodies to PD-1 and PD-L1 are now FDA-approved for the treatment of Hodgkin's disease, melanoma, merkel cell, non-small cell lung, head and neck, gastroesophageal, bladder, urothelial, renal cell, and hepatocellular cancers, and are being tested in numerous other types of cancer. Here, CD274 is linked to cancer.